About Epidaris
Epidaris is the innovation center of Segal Pharma Group, focusing on pioneering new solutions within the pharmaceutical and medical fields. Our expertise encompasses drug repurposing, herbal medicinal products, medical aesthetics, and medical devices.
Epidaris's team of seasoned professionals brings extensive experience in R&D methodologies, clinical development, regulatory affairs, production, IP management, and marketing.
With a legacy of over five decades, Segal Pharma Group has a rich history in the pharmaceutical industry, distributing more than 600 pharmaceutical products and medical devices in over 40 countries.
We are dedicated to fostering innovation and excellence in every project we undertake.
WHAT EPIDARIS DOES
Epidaris partners with healthcare and academic institutions and transforms early-stage technologies with significant market potential into commercialized pharmaceutical products. Epidaris oversees the entire journey, from further development, upscaling, clinical trials, regulatory approvals, and finally into commercial launch, ensuring that high-potential innovations swiftly reach the market. This approach allows our innovator partners to concentrate on their next big idea while enjoying the financial benefits of a commercialized product. Epidaris takes care of the heavy lifting, so innovators can keep innovating.
Leveraging an extensive worldwide network, Epidaris strategically positions each new technology and company within established markets and distribution channels, ensuring effective market entry and growth.
Epidaris's Vision
Our mission is to be a platform that effectively transforms ideas into thriving companies with products that improve patients' lives.
By partnering with forward-thinking institutions and supporting technologies through all stages of development, we aim to make a lasting impact on global health.
Idea to Market Journey
Innovators develop early-stage pharmaceutical products and technologies with significant market potential.
Epidaris facilitates and fully funds R&D and scale-up within our existing infrastructure. We advance prototypes into full-scale products through rigorous testing, optimization, and clinical trials.
Innovators enjoy the financial benefits of a successful, commercialized pharmaceutical product.
Epidaris scouts for promising technologies, forges mutually beneficial agreements with innovators, and establishes efficient technology-transfer protocols.
Epidaris brings the product to market, managing everything from regulatory approval to commercial launch.
Fields of Interest
Drug Repurposing
Asthetic Formulations
Drug Delivery Forms
Herbal and Fungi-Based Medicines
Medical Devices
From concept to market- Expertise at every stage
GMP-accredited production facilities and an in-house compounding pharmacy
Advanced lab space with chemical and biological capabilities, driven by a skilled team
Experience and capabilities in conducting Phase I and Phase II trials, as well as observational and post-market studies
Extensive proven regulatory experience across various countries and regulatory levels
In-house patent creation and protection, supported by expert consultants
Navigate complex regulations
to quickly reach patients.
A global network of established markets and distribution channels with over 1000 B2B partners
Demonstrated commercial success in over 40 countries, including markets in Israel and Europe.
Meet the Team
Our team consists of several experienced leaders in the pharmaceutical industry, possessing deep knowledge in R&D methodologies, clinical development, regulatory compliance, and marketing.
Portfolio
Epidaris is the innovation platform of the following companies, helping them grow and integrate new technologies for diverse treatment applications.
We are constantly looking to expand Segal Pharma Group's portfolio, allowing us to bring game-changing health solutions to patients.
Panaxia is a global pharmaceutical company that develops and markets innovative cannabis products at pharmaceutical standards for a wide range of medical indications.
-
Markets: Active in Germany, France, Poland, Israel, the the UK.
-
Products: Offers a wide range of products including oils and vapes
-
Achievements: The only company globally with marketing authorization from the Western Health Authority for cannabis tablets; a leading provider in the French governmental pilot to regulate the medical cannabis market.
-
Facilities: The first EU-GMP and IMC-GMP approved manufacturing facility in Israel and an EU-GMP certified facility in Malta.
Luminera Pharm is a compounding pharmacy that specializes in high-quality bioidentical hormonal therapies. Their bioidentical hormone pellet implants, a drug delivery method for subcutaneous sustained release over several months, represent an innovative breakthrough treatment for hormonal decline and imbalance in women and men, especially during menopause.
-
Product Range: Includes over 100 formulas with various pharmaceutical active ingredients across multiple dosage forms, tailored for commercial markets and clinical trials. This includes semisolid preparations (creams, emulsions, ointments, gels), solid preparations (tablets, capsules), and sterile preparations (implants, solutions, gels).
-
Quality Assurance: Manufactured under a strict GMP quality system approved by the Israeli Health Ministry.
Glyance specializes in aesthetic innovation, focusing on dermal fillers.
-
Product Range: Offers a versatile range of formulas designed to enhance natural aesthetics and provide excellent lifting and filling capacities. Dermal fillers are helpful for addressing wrinkles, lip shaping, and jaw contouring.
-
Innovative Technology: Utilizes unique 2By2 Matrix Technology to produce tailored solutions.
-
Clinical Excellence: Ensures the highest standards of quality and efficacy through continuous clinical work.
-
Regulatory Excellence: Certified as an implantable medical device.
-
Commercial Activity: Actively selling products to B2B customers.
Axecium is dedicated to developing innovative plant- and fungi-based therapies for various medical indications.
-
Research Focus: Identifies natural compounds and active ingredients that influence biological and chemical mechanisms.
-
R&D Pipeline: Developing treatment options for hyperpigmentation from hormonal imbalance and cluster headaches.
-
Product Development: Utilizes these findings to create scientifically-based, high-quality, and safe pharmaceutical products.
Prudentix Ltd. is an R&D company focused on the development and sale of innovative medical devices in the fields of dentistry, orthopedics, and dermatology.
-
Research Focus: Develop products targeting various diseases and traumas, designed to regenerate tissues.
-
Innovative Formulations: Utilizes patented formulations with unique structural properties to achieve state-of-the-art functionality for healing.
-
Product Range: Includes medical devices for periodontal pockets, gingivitis, halitosis, and oral hygiene, with a focus on chemical substances and anti-inflammatory properties.
Strategic Collaborations
Epidaris collaborates with universities, hospitals, and research institutions worldwide to identify and commercialize innovative technologies and help bring solutions to patients. By combining academic expertise with our strategic planning and market innovation capabilities, we bridge the gap between discovery and commercialization.
